DOCSLIB.ORG

HSC Clinical Trials Controversy Continues

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
HSC Clinical Trials Controversy Continues © 1999 Nature America Inc. • http://medicine.nature.com LETTERS TO THE EDITOR Research Institute for several years. When HSC clinical trials controversy continues Spino began working for Apotex, he left the staff of the hospital but became an To the editor—We write to correct inaccu- American Society of Hematology and in unpaid consultant to HSC. Since joining racies in your October issue editorial and the New England Journal of Medicine (339, Apotex, Spino has not maintained a lab- news article concerning the controversial 417; 1998). oratory at HSC, but has done collabora- clinical trial involving Nancy Olivieri, After Apotex did not renew the L-1 clin- tive research in Koren’s laboratory. Koren The Hospital for Sick Children (HSC) and ical trial contract, Olivieri wished to con- and Spino co-supervised a graduate stu- Apotex Inc. Whereas there is no question tinue to use L-1 to treat thalassemia dent and a research technician. Spino that this case is complicated and that patients at HSC and Apotex agreed to pro- was, and continues to be, a professor at there are as many interpretations of the vide the drug under the Canadian gov- The University of Toronto. facts as there are involved parties, the ernment’s Emergency Drug Release (EDR) Arnold Naimark, former dean of Medi- allegation that the HSC administration program. Later, Apotex on several occa- cine and President of the University of “completely failed to support the efforts sions contacted hospital officials request- Manitoba, has conducted a review to of Olivieri” is false and the implication ing that the hospital help them gain determine the facts and circumstances of that we did not support Olivieri’s right to access to the data generated while Olivieri this complex case. We anticipate that his publish is unwarranted. treated patients under the EDR program, report will further clarify facts in the case In a letter dated 24 May 1996, Apotex and HSC supported Olivieri in refusing and make useful recommendations for notified Olivieri (and her collaborator these requests. Olivieri’s complaint that future practice at the Hospital for Sick Gideon Koren) that they would not her data was used without her permission Children. [As Nature Medicine went to renew the contract supporting the trial of was brought to The University of Toronto press this report was released and is avail- L-1 (Deferiprone). Apotex also warned for adjudication (in keeping with the uni- able at http://www.sickids.on.ca/ HSCWeb/ Olivieri and Koren that they would pur- versity’s Procedures to Address and Manage zReview/TheReview). Further- more, a sec- sue legal remedies if they breached the Scientific Misconduct). An investigating ond-phase review is also planned to obligations in their previous three-year committee was established and reported examine current hospital policies and contract. In a letter dated 25 May, Olivieri in September 1997, dismissing the allega- procedures relating to the broader issues and Koren informed the hospital that tion and exonerating the faculty member of clinical trials and third-party funding. they had already sought legal counsel, against whom the charge was made. The outcome of these reviews may also be who had advised them to contact the The connection between HSC and of value to other institutions. http://medicine.nature.com • Canadian Medical Protective Association Michael Spino, now a vice president of (CMPA). When Olivieri subsequently met Apotex, should be clarified. Spino was a MANUEL BUCHWALD1 & with university officials on 6 June, and member of The Hospital for Sick Children HUGH O'BRODOVICH2 with hospital representatives on 18 July, she was represented by a lawyer from DNAVEC gene therapy on course McCarthy Tetrault, the firm retained by the CMPA. It was not until the hospital In your November issue, you carried a news story (“Japan renews gene therapy ef- board of directors initiated an indepen- forts”) regarding progress on gene therapy in Japan. We think that your discussion of dent external review that Olivieri DNAVEC Research was misleading, and we would like to clarify a few points. 1999 Nature America Inc. requested legal assistance from the hospi- We disagree with your suggestion that DNAVEC has failed in its aims or is behind © tal in this matter. Olivieri has been con- schedule. Our aim is to develop new gene therapy-related technologies, to sell these tinuously represented by lawyers from to our investors and third parties and to proceed to clinical trials with companies ex- McCarthy Tetrault. perienced in clinical trials. At our inception (March 1995) and thereafter, we stated At the 18 July 1996 meeting, Olivieri our intention to invest three to five years in new vector development, followed by and her lawyer requested that the hospi- animal studies, development of the methodologies required for the initial phase of tal take a position against Apotex, back- the commercial production of vectors, and preliminary safety studies. Our develop- ing her scientific findings. The hospital’s ment of a Sendai virus-based vector is on schedule and has received favorable re- opinion was that the conflict was a sci- views from the scientific review committee of the Organization for Pharmaceutical entific dispute among Olivieri, Koren, Safety and Research, an extra-governmental organization of the Ministry of Health Apotex and several other scientists and Welfare, Japan. regarding the effectiveness of L-1 and, as Your news story failed to recognize our precise research policy—we are neither a such, should be resolved through the contract vector production facility nor a safety assessment facility. Incidentally, the scientific literature. The hospital sup- preparation to launch DNAVEC started in 1993, well in advance of the approval of ported and encouraged Olivieri’s initia- the first gene therapy clinical trial in Japan. tive to submit her findings for presenta- tion at the December 1996 meeting of MAMORU HASEGAWA the American Society of Hematology, Managing Director which she did. She also reported her find- DNAVEC Research ings in an article in the Medical Post (Jan- 1-25-11 Kannondai, Tsukuba-shi uary 1997), in April 1997 at the Sixth Ibaraki 305 International Conference on Tha- Japan lassemia and Hemoglobinopathies, and [email protected] at the December 1997 meeting of the 2 NATURE MEDICINE • VOLUME 5 • NUMBER 1 • JANUARY 1999 © 1999 Nature America Inc. • http://medicine.nature.com LETTERS TO THE EDITOR 1Director, The Hospital for Sick Children latory agencies. This recommendation president of Apotex, appeared on the let- Research Institute, Chief of Research, The was dismissed by the senior HSC admin- terhead of the Division of Clinical Hospital for Sick Children, Molecular and istration, who stated that “the matter Pharmacology at HSC as recently as Medical Genetics, University of Toronto, could be settled without the help of March 1998. Spino has confirmed that 2Chief of Paediatrics, The Hospital for Sick regulatory agencies.” Fortunately, the he maintained laboratory space at HSC, Children, Chairman of Paediatrics, Faculty of CMPA, recognizing that I was “subject to a fact allegedly unknown by the director Medicine, University of Toronto the ethical obligations of a physician as of the hospital’s research institute. well as the obligations imposed by the Spino’s technician confirmed in August Olivieri replies—The facts of this case are Institutional Review Board, the 1998 that work on Deferiprone was still quite straightforward. The allegation Declaration of Helsinki, and Medical ongoing in his laboratory. that the Hospital for Sick Children Research Council of Canada’s Code Finally, as is now a matter of public (HSC) and the University of Toronto of Conduct for Research Involving record, the pursuit of a $20 million do- “completely failed to support the efforts Humans,” subsequently agreed to sup- nation by Apotex to the University of of Olivieri” is absolutely true, as is the port disclosure to the Canadian Health Toronto is the ‘top’ priority of the implication that it did not support my Protection Branch. Noting that I was University of Toronto. right to publish findings about L-1 “rightly concerned about the safety and Throughout 1997 and 1998, I and sev- (Deferiprone). well-being of persons throughout the eral other concerned scientists have re- Ultimately, the only support to me for world,” the CMPA observed that such quested an independent inquiry into legal protection came from the Canadian disclosure would be “in compliance with this matter. We have refused to partici- Medical Protective Associa-tion (CMPA), statutory requirements.” That I was able pate in Naimark’s ‘review’ because of an organization that serves to protect to submit and present data at scientific grave concerns about the fairness of physicians in Canada from legal threats meetings was solely the result of support a panel appointed by one of the arising in the practice of medicine. The ultimately provided by CMPA. parties implicated in this controversy. CMPA first limited its support to the In January 1997, two abstracts endors- Therefore, presentation of the legal issue of full disclosure of the perceived ing the long-term effectiveness of records, transcripts of tape-recorded risk of Deferiprone to my Toronto pa- Deferiprone presented to a scientific messages, other communications and tients only. The CMPA declined to sup- meeting were co-authored by Apotex- unassailable facts that will not be pre- port disclosure of perceived risks to paid research fellows, a full-time em- sented to Naimark will be included in a patients in international trials (of which ployee of Apotex and two University of future full, independent and unbiased http://medicine.nature.com • 1,2 I was the chair of the steering commit- Toronto investigators . These abstracts inquiry. tee), to regulatory agencies (to which ap- and other subsequent communications3 plications were being made by Apotex continue to provide a favorable interpre- NANCY OLIVIERI for licensing, based in large part on ear- tation of data arising from the Toronto Professor of Pediatrics and Medicine, University lier work by us) or to the scientific com- clinical trials of Deferiprone directed by of Toronto, Canada munity.
Load more

Recommended publications
  • 1 February 2019 CURRICULUM VITAE GIDEON KOREN
    February 2019 CURRICULUM VITAE GIDEON KOREN Cardiovascular Research Center Rhode Island Hospital, Coro West 5103 Providence, RI 02903 Phone: (401) 444-4629 Fax: (401) 444-9203 [email protected] Education: 1969-1977 M.D., Hebrew University, Hadassah Medical School, Jerusalem, Israel Postdoctoral Training: Internships and Residencies: 1976-1977 Rotating Internship, Hadassah Medical Center, Jerusalem 1981-1982 Residency Program, Department of Medicine A, Hadassah Medical Center, Jerusalem Fellowships: 1983-1985 Fellow in Cardiology, Department of Cardiology, Hadassah Medical Center, Jerusalem 1985-1987 Research Fellow in Pediatrics, Harvard Medical School, Boston 1985-1989 Research Fellow, (Molecular Biology), Department of Cellular and Molecular Physiology and the Department of Cardiology, Children's Hospital Postgraduate Honors and Awards: 1969-1976 Prizes for "excellence in studies", Hebrew University, Hadassah Medical School 1976 Elected class representative for medical student exchange program, Mount Sinai School of Medicine, New York 1978 Faculty Prize for M.D. Thesis: "Semiquantitative determination of liver specific antigens in the urine of rats with toxic hepatic necrosis" 1985-1987 Fogarty International Fellow 1985-1987 Fulbright Scholar 1987-1988 Bugher Fellow 1989 Milton Award 1994-1999 American Heart Association Established Investigator Award 1995 Ad hoc Reviewer - Program Project Review Committee, NHLBI 1 2006-2011 Member of the ESTA NIH Study Section 2007- Member of the Data Safety Monitoring Board of NHLBI- sponsored VEST/PREDICTS 2013 Heart Rhythm Journal: Best basic research article for the year (one of four) 2017 Member of Editorial Board - Circulation Arrhythmia Military Service: 1977-1978 I.D.F. - Physician of a Tank Regiment 1979-1980 I.D.F. - Director of the training course for military physicians 1980-1981 I.D.F.
    [Show full text]
  • Lessons at the Hospital for Sick Children
    Docket: 1-5519 Initial: JN Customer: CMAJ Oct 20/98 15519 October 20/98 CMAJ /Page 955 Constraints of interest: lessons at the Hospital for Sick Children Robert A. Phillips, PhD; John Hoey, MD Editorial Éditorial As you now [sic], paragraph 7 of the LA-02 Contract provides that all information whether written or not, obtained or generated by you during the term of the LA-02 Contract and for a period of three years thereafter, shall be and remain secret and confidential and shall Dr. Phillips is Executive not be disclosed in any manner to any third party except with the prior written consent of Director of the National Apotex. Please be aware that Apotex will take all possible steps to ensure that these obliga- Cancer Institute of Canada, tions of confidentiality are met and will vigorously pursue all legal remedies in the event that there is any breach of these obligations. Toronto, Ont. He was director of Immunology and Excerpt from a letter dated May 24, 1996, from Dr. Michael Spino, Vice President Cancer Research at the of Scientific Affairs, Apotex Research Inc., to Dr. Nancy Olivieri. Hospital for Sick Children’s Research Institute from 1991 The truly remarkable thing about this paragraph is that it came to be written to 1996. Dr. Hoey is Editor- at all. That an internationally renowned children’s hospital would have no for- in-Chief of CMAJ. mal mechanism to scrutinize contracts and that seasoned researchers at the hos- pital, faculty members at one of Canada’s most prestigious medical schools, would sign a contract containing a 3-year gag clause to prevent the unautho- CMAJ 1998;159:955-7 rized release of any findings is astounding.
    [Show full text]
  • Ontogeny of Renal P-Glycoprotein Expression in Mice: Correlation with Digoxin Renal Clearance
    0031-3998/05/5806-1284 PEDIATRIC RESEARCH Vol. 58, No. 6, 2005 Copyright © 2005 International Pediatric Research Foundation, Inc. Printed in U.S.A. Ontogeny of Renal P-glycoprotein Expression in Mice: Correlation with Digoxin Renal Clearance NATASHA PINTO, NAOMI HALACHMI, ZULFIKARALI VERJEE, CINDY WOODLAND, JULIA KLEIN, AND GIDEON KOREN Division of Clinical Pharmacology [N.P., NH, J.K., G.K.], Division of Clinical Biochemistry [Z.V.], The Hospital for Sick Children, Toronto, Ontario, M5G 1X8, Canada; Department of Pharmacology [N.P., C.W., G.K.], University of Toronto, Toronto, Ontario, M5S 1A8, Canada ABSTRACT Digoxin is eliminated mainly by the kidney through glomer- was studied in mice of the same age groups. Newborn and Day ular filtration and P-glycoprotein (P-gp) mediated tubular secre- 7 levels of both mdr1a and mdr1b were marginal. Day 21 mdr1b tion. Toddlers and young children require higher doses of levels were significantly higher than both Day 14 and Day 28 digoxin per kilogram of bodyweight than adults, although the levels. Digoxin clearance rates were the highest at Day 21, with reasons for this have not been elucidated. We hypothesized there significant correlation between P-gp expression and clearance is an age-dependant increase in P-gp expression in young chil- values. Increases in digoxin clearance rates after weaning may be dren. The objectives of this study were to elucidate age- attributed, at least in part, to similar increases in P-gp expression. dependant expression of renal P-gp and its correlation with (Pediatr Res 58: 1284–1289, 2005) changes in the clearance rate of digoxin.
    [Show full text]
  • Drugs During Pregnancy and Lactation: New Solutions to Serious Challenges
    Obstetrics and Gynecology International Drugs during Pregnancy and Lactation: New Solutions to Serious Challenges Guest Editors: Gideon Koren, Shannon Clark, and Doreen Matsui Drugs during Pregnancy and Lactation: New Solutions to Serious Challenges Obstetrics and Gynecology International Drugs during Pregnancy and Lactation: New Solutions to Serious Challenges Guest Editors: Gideon Koren, Shannon Clark, and Doreen Matsui Copyright © 2012 Hindawi Publishing Corporation. All rights reserved. This is a special issue published in “Obstetrics and Gynecology International.” All articles are open access articles distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Editorial Board Sean Blackwell, USA Howard D. Homesley, USA Julian T. Parer, USA Diane C. Bodurka, USA Shi-Wen Jiang, USA Faustino R. Perez-L´ opez,´ Spain Curt W. Burger, The Netherlands Marc J. N. C. Keirse, Australia Tonse N.K. Raju, USA Linda D. Cardozo, UK Russell K. Laros Jr., USA Neal S. Rote, USA Nancy Chescheir, USA Jonathan Ledermann, UK Giovanni Scambia, Italy Robert Coleman, USA Kimberly K. Leslie, USA Peter E. Schwartz, USA W. T. Creasman, USA Lawrence D. Longo, USA John J. Sciarra, USA Mary E. D’Alton, USA G. A. Macones, USA J. L. Simpson, USA Gian Carlo Di Renzo, Italy Everett Magann, USA Anil Sood, USA Keith A. Eddleman, USA James A. McGregor, USA Wiebren A. A. Tjalma, Belgium Edmund F. Funai, USA Liselotte Mettler, Germany J. R. Van Nagell, USA Thomas Murphy Goodwin, USA Daniel R. Mishell, USA John G. van Vugt, The Netherlands WilliamA.Grobman,USA Bradley J.
    [Show full text]
  • The Drug Trial: Nancy Olivieri and the Science Scandal That Rocked the Hospital for Sick Children
    The Drug Trial: Nancy Olivieri and the Science Scandal that Rocked the Hospital for Sick Children Miriam Shuchman, Random House, 451 pp., $34.95. Review written by: Arthur Schafer Nancy Olivieri is famous for raising doubts about an experimental drug with which she was treating thalassemia patients. Her principled stand, and the resulting scandal, led universities to offer researchers some protection against illegitimate drug company pressure. Medical journals changed their publication rules. Research hospitals changed their policies. She became an international icon. Apotex, the drug company which tried to silence her, has attracted international opprobrium. The company threatened to sue Olivieri if she publicly revealed her fears about the inadequacy of their drug, deferiprone. She sued them for libeling her; they sued her ($20 million) for libeling their drug. Apotex claims still to believe in the virtue of deferiprone, but the company has been heavily criticized for conduct which many have interpreted as placing profits ahead of patient safety. Apotex is not alone in the dock of public opinion. Every week seems to bring some new scandal involving drug company suppression of negative data: think Prozac [Eli Lilly], Vioxx [Merck] and Celebrex [Pfizer]. Big Pharma is facing a crisis. Public trust in drug company sponsored research is plummeting. Olivieri’s hospital, Sick Kids, and her university, the U of T, have also taken a public drubbing for failing to provide her with effective support as she struggled with Apotex. Actually, not only was Olivieri denied effective support, she was fired from her position and experienced harassment of almost every kind.
    [Show full text]
  • The Drug Trial
    Vol. 24 No. 4 October 2005 REVIEW ARTICLE Miriam Shuchman, The Drug Trial. Nancy Olivieri and the Science Scandal that Rocked the Hospital for Sick Children, Random House, Canada 2005, ISBN: 0-679- 31084-3 The Drug Trial follows the synthesis of deferiprone in England in the 1980s, and growing hopes that it might replace the then standard treatment for thalassemia, deferoxamine, which was effective but inconvenient and uncomfortable. Thalassemia is the commonest single gene disorder in the world. Prior to deferoxamine, it led to disfigurement, early deaths, and social stigma. One of the standard bearers of deferiprone was Nancy Olivieri, who in the late 1980s and early 1990s was working at the Hospital for Sick Children, and the University of Toronto. Once an enthusiast for deferiprone, Olivieri became aware that it did not seem to work as well as deferoxamine. At this point in its evolution, the main deferiprone trial was sponsored by a pharmaceutical company, Apotex. Apotex neither welcomed Olivieri’s growing suspicions nor shared her belief that the patients in the trial should be informed of emerging doubts about the new drug. Rather than warn, the drug was removed from Toronto overnight. When patients turned up for their treatment, they found a bewildered hospital staff, who had neither a treatment nor an explanation to offer. The deferiprone study continued elsewhere. Many of the reviewers of this book have conflicts of interests, but have not always made them fully clear. Miriam Shuchman gives no indication about any conflicts she might have, other than what might be inferred between the lines.
    [Show full text]
  • Legal Issues Surrounding Privately Funded Research Cause Furore in Toronto Features Miriam Shuchman, MD Chroniques
    Docket: 1-5519 Initial: JN 15519 October 20/98 CMAJ /Page 983 Customer: CMAJ Oct 20/98 Legal issues surrounding privately funded research cause furore in Toronto Features Miriam Shuchman, MD Chroniques In brief Dr. Miriam Shuchman lives in Toronto and teaches in the TORONTO PHYSICIAN MIRIAM SHUCHMAN has spent the last 4 months tracking the re- Department of Psychiatry at search issues surrounding a controversial clinical trial conducted in Toronto. Much the State University of New of the information appearing in this article was gathered while she was preparing a York, Buffalo. segment for the CBC Radio program Quirks and Quarks. Earlier, she had reported on similar issues in the US for the Annals of Internal Medicine. CMAJ 1998;159:986-9 lthough research partnerships between medical academics and private com- panies are proliferating, a case that was widely publicized in Toronto this ß See related article page 955 Asummer makes clear that these partnerships do not always go smoothly. When the company does not like the research findings, it may try to keep them se- cret. And if the company is also a major philanthropic force in the community, there is the potential for conflicts of interest for the institutions involved. The incident itself is relatively simple, but the issues it raises are not. Internist Nancy Olivieri of the Hospital for Sick Children (HSC) and the University of Toronto partnered with a pharmaceutical company, Apotex Inc., to test a drug. Barry Sherman, the head of Apotex, is a generous donor to causes in Toronto and across the country.
    [Show full text]
  • Dean's Report 2012
    The Dean’S REPOrt SCHULICH SCHOOL OF MEDICINE & DENTISTRY ANNUAL PERFORMANCE REVIEW | 2012 CONTENTS 03 A Message from Dr. Michael J. Strong 49 Office of Interprofessional Health Education 05 Building Toward the Future with Mr. Dwayne Martins and Research (IPHER) 51 Centre for Education Research and Innovation 06 OPTIMIZING LIFE-LONG HEAltH (CERI) 07 Strategic Plan 12-18 Month Deliverables 54 Continuing Professional Development (CPD) 55 Continuing Dental Education (CDE) 09 OPERATIONS & ADMINISTRATION 56 Clinical Skills Learning Program 10 Space and Facilities 57 Program Evaluation Office 11 Finance 12 Human Resources 58 FINANCIAL AccESSIBILITY 16 Alumni Relations and Development 59 Scholarships, Awards and Bursaries 17 Communications and Marketing 20 Media Relations 61 RESEArcH 22 Information Services 62 Research Highlights 23 Strategic Technology Commons (STC) 63 Canada Research Chairs 64 Notable Research Publications 25 OUTSTANDING EDUCATION 65 Research Funding 26 Program Offerings 66 Robarts Research Institute 27 Doctor of Medicine (MD) Program 32 Doctor of Medicine (MD) - Windsor Program 67 AWArdS 34 Doctor of Dental Surgery (DDS) Program 68 Awards Received by Faculty, Staff and Students 37 Internationally Trained Dentist Program (ITD) 38 Bachelor of Medical Sciences (BMSc) 72 INTERNATIONALIZATION 40 Postgraduate Medical Education (PGME) 73 Office of Global Health 42 Southwestern Ontario Medical Education Network (SWOMEN) 78 SOCIAL RESPONSIBILITY 44 Graduate Studies and Postdoctoral Affairs Office 79 Social Responsibility Highlights 45 Clinical Graduate Programs 46 CIHR Strategic Training Programs 47 Combined Degree Programs 48 Other Programs 09 25 61 THE DEAn’S REPORT | 2012 2 A MESSAGE FROM DR. MICHAEL J. STRONG DEAN, SCHULICH SCHOOL OF MEDICINE & DENTISTRY The Schulich School of Medicine & Dentistry welcomed the arrival of 2012 ready to advance its work as set out in several new plans.
    [Show full text]
  • Cancer in Pregnancy and Lactation: the Motherisk Guide Edited by Gideon Koren and Michael Lishner Copyright Information More Information
    Cambridge University Press 978-1-107-00613-3 - Cancer in Pregnancy and Lactation: The Motherisk Guide Edited by Gideon Koren and Michael Lishner Copyright Information More information Cancer in Pregnancy and Lactation: The Motherisk Guide Edited by Gideon Koren Founder and Director, Motherisk Program and Professor of Pediatrics, Pharmacology, Pharmacy and Medical Genetics, University of Toronto, Canada. Michael Lishner Professor of Medicine, Sackler Faculty of Medicine, Tel Aviv University and Head of Department of Medicine A, Meir Hospital, Kfar Saba, Israel. © in this web service Cambridge University Press www.cambridge.org Cambridge University Press 978-1-107-00613-3 - Cancer in Pregnancy and Lactation: The Motherisk Guide Edited by Gideon Koren and Michael Lishner Copyright Information More information CAMBRIDGE UNIVERSITY PRESS Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, São Paulo, Delhi, Tokyo, Mexico City Cambridge University Press The Edinburgh Building, Cambridge CB2 8RU, UK Published in the United States of America by Cambridge University Press, New York www.cambridge.org Information on this title: www.cambridge.org/9781107006133 # Cambridge University Press 2011 This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press. First published 2011 Printed in the United Kingdom at the University Press, Cambridge A catalog record for this publication is available from the British Library Library of Congress Cataloging-in-Publication Data Cancer in pregnancy and lactation : the Motherisk guide / edited by Gideon Koren, Michael Lishner. p. ; cm. Includes bibliographical references and index.
    [Show full text]
  • Health Canada Documents
    HEALTH CANADA DOCUMENTS City of Roses Wind Energy LLC TX20-02 Exhibit 3 Wind turbine sound pressure level calculations at dwellings Stephen E. Keith, Katya Feder, Sonia A. Voicescu, Victor Soukhovtsev, Allison Denning, Jason Tsang, Norm Broner, Tony Leroux, Werner Richarz, and Frits van den Berg Citation: The Journal of the Acoustical Society of America 139, 1436 (2016); doi: 10.1121/1.4942404 View online: https://doi.org/10.1121/1.4942404 View Table of Contents: https://asa.scitation.org/toc/jas/139/3 Published by the Acoustical Society of America ARTICLES YOU MAY BE INTERESTED IN Wind turbine sound power measurements The Journal of the Acoustical Society of America 139, 1431 (2016); https://doi.org/10.1121/1.4942405 Exposure to wind turbine noise: Perceptual responses and reported health effects The Journal of the Acoustical Society of America 139, 1443 (2016); https://doi.org/10.1121/1.4942391 Personal and situational variables associated with wind turbine noise annoyance The Journal of the Acoustical Society of America 139, 1455 (2016); https://doi.org/10.1121/1.4942390 Estimating annoyance to calculated wind turbine shadow flicker is improved when variables associated with wind turbine noise exposure are considered The Journal of the Acoustical Society of America 139, 1480 (2016); https://doi.org/10.1121/1.4942403 Self-reported and measured stress related responses associated with exposure to wind turbine noise The Journal of the Acoustical Society of America 139, 1467 (2016); https://doi.org/10.1121/1.4942402 Low-frequency noise from large wind turbines The Journal of the Acoustical Society of America 129, 3727 (2011); https://doi.org/10.1121/1.3543957 Wind turbine sound pressure level calculations at dwellings Stephen E.
    [Show full text]
  • My Own Invention: Gideon Koren - Telling Tails: Children's Literature Goes to the Hospital
    The Looking Glass : New Perspectives on Children’s Literature - !14 - Vol 1, No 3 (1997) My Own Invention: Gideon Koren - Telling Tails: Children's Literature Goes to the Hospital. ! My Own Invention ! Telling Tails: Children's Literature Goes to the Hospital Gideon Koren ! Gideon Koren is an Israeli-Canadian pediatrician, clinical pharmacologist, toxicologist, author and a composer of Israeli popular music. In 1992 he founded the Bear Theatre at the Hospital for Sick Children in Toronto, the only such theatre worldwide where health professionals perform weekly for hospitalized children and their families. The musical "Tails" — script, songs, direction and children's book by Koren — has served as a model for other hospitals. In July 2007 the theatre celebrated 15 years and 750 shows. At the hospital, Koren goes by the nickname "Gidi" and takes pride in wearing eccentric hats to the performances of "Tails." ! As a doctor and children's author, I have two distinct careers. This is the story of how they came together. I arrived in Canada in 1982, after writing Hebrew children's books and music in Israel for over a decade. Three of my books were commercially staged; six were recorded as records and audio cassettes. While establishing my academic career in Toronto at The Hospital for Sick Children and The University of Toronto, I continued to publish children's books in Israel. But I missed the direct contact with children through the stage and the recording studio. After nine years, I realized that I was missing a vital and intimate activity, and ignoring a major personal need.
    [Show full text]
  • Explosive Judicial Review Puts Lens on Gideon Koren and Sickkids
    Explosive judicial review puts lens on Gideon Koren and SickKids www.macleans.ca /society/health/explosive-judicial-review-puts-lens-on-gideon-koren-and-sickkids/ Anne Kingston Dr. Gideon Koren, director of Motherisk. (Hospital for Sick Children) When retired Ontario Court of Appeal Justice Susan Lang submitted her independent review of the Hospital for Sick Children’s Motherisk Hair Testing Laboratory to the provincial government in December, she appended a cover letter to the province’s attorney general. This letter, released with the full report, described the world-renowned hospital’s testing of hair for drugs and alcohol used in thousands of child services cases and criminal courts as “inadequate and unreliable.” Testing “did not meet internationally recognized forensic standards,” Lang added, ending with this: “The use of the laboratory’s hair-testing evidence in child protection and criminal proceedings has serious implications for the fairness of those proceedings and warrants an additional review.” Lang’s letter, rather than her explosive 366-page report, was widely quoted in the surprisingly muted media coverage of her investigation, which was commissioned more than a year ago after the province’s highest court set aside the 2009 conviction of Tamara Broomfield on various charges, including assault causing bodily harm, aggravated assault, failing to provide the necessities of life and administering a noxious substance. That decision by the court put the spotlight on inadequacies in evidence produced by the Motherisk drug-testing lab (MDTL) and the “expert” testimony of its director, Gideon Koren. Both contributed to Broomfield being sentenced to seven years for various offences, including two counts related to administering a near-lethal dose of cocaine to her two-year-old son, who had previously been hospitalized with an unexplained seizure.
    [Show full text]